Objectives Pigment epithelium-derived factor (PEDF), a multifunctional endogenous glycoprotein, has a very wide range of biological actions, notably in bone homeostasis. The question has been raised regarding the place of PEDF in the treatment of bone disorders and osteosarcoma, and its potential for tumour growth suppression. Methods The PubMed database was used to compile this review. Key findings Pigment epithelium-derived factor's actions in osteoid tissues include promoting mesenchymal stem cell commitment to osteoblasts, increasing matrix mineralisation, and promoting osteoblast proliferation. It shows potential to improve therapeutic outcomes in treatment of multiple cancer types and regrowth of bone after trauma or resection in animal studies. PEDF may possibly have a reduced adverse effect profile compared with current osteo-regenerative treatments; however, there is currently very limited evidence regarding the safety or efficacy in human models. Summary Pigment epithelium-derived factor is very active within the body, particularly in osseous tissue, and its physiological actions give it potential for treatment of both bone disorders and multiple tumour types. Further research is needed to ascertain the adverse effects and safety profile of PEDF as a therapeutic agent.
Introduction to pigment epitheliumderived factor
Pigment epithelium-derived factor (PEDF) is a 50-kDa endogenous multifunctional glycoprotein of the non-inhibitory serine protease inhibitor (serpin) family, secreted by cells such as those of the epithelial retinal pigment, [1] skeletal myocytes, hepatocytes and adipocytes. [2] Encoded by SERPINF1 gene on chromosome17p13 in various human tissues, PEDF has an a/ß core serine-protease inhibitor domain, and its tertiary structure includes ten a-helices and three ß-sheets. Despite its structure and family classification, PEDF does not display the protease-inhibition activity that is characteristic of other serpins. [3] ( Figure 1 ). Pigment epithelium-derived factor's endogenous roles include angiogenesis inhibition, immunomodulation [4] and protection against oxidative stress. [5] PEDF is important as a regulator of the vascular development of the eyes, [6] reducing angiogenesis whilst improving survival and proliferation of pericytes [7] (a structural part of microvessels) and decreased PEDF levels have been associated with multiple conditions including hypoxic retinal neovascularisation and diabetic macular oedema. [8, 9] Such angiogenesis inhibition occurs via reduction in production of vascular endothelial growth factor (VEGF), [10] a potent pro-angiogenic factor, and modulation of its receptors-thus PEDF has been proposed as a possible therapeutic agent for prevention of angiogenesis in tumours. [11] It has also demonstrated the ability to regulate and renew the neural stem cells niche in the brain, causing proliferation and maintenance of progenitors in an undifferentiated state. [12] Additionally, PEDF plays a role in metabolic homeostasis; higher levels of PEDF have been associated with metabolic dysfunction/disorders including obesity, polycystic ovarian syndrome (PCOS), increase of body mass index, fasting triglycerides and glucose, and have also been shown to be associated with insulin resistance in both mice and humans. [2, [13] [14] [15] PEDF has been found to display actions against several cancer types via many different mechanisms including inhibition of migration and proliferation of endothelial cells, reduction in angiogenesis in tumours/ their surrounding environment and increased apoptosis. [16] Thus, involvement in the treatment of cancer is a current area interest for PEDF research. Also, PEDF affects the formation and maintenance of bone tissues within the body. [17] This review covers PEDF's actions regarding bone, investigates potential applications for PEDF, and outlines potential adverse effects that may affect its therapeutic use.
Overview of bone homeostasis
For bone formation to occur, mesenchymal stem cells (MSCs) differentiate to precursor osteoblast cells and migrate from bone marrow to the surface, where they become adult osteocytes and work to deposit minerals to form the bone matrix. A large degree of plasticity and transdifferentiation occurs between different MSC lineages including chondrocytes, adipocytes and osteocytes and thus osteogenic differentiation must be preferentially induced. [18] Particularly, differentiation between osteogenic and adipogenic lineage is very closely related as generation of adipose tissues in bone marrow is critical; it plays a major endocrine function, secreting hormones known as 'adipokines' involved in body weight control, inflammation, diabetes and more.
[19] However, excessive bone marrow adipogenesis leads to reduced bone mineral density, weak/spongy bones, and increases propensity toward osteoporosis.
Factors controlling bone formation include bone morphogenetic proteins (BMPs), homeodomain transcription factor MSX2 and runt-related transcription factor-2 (RUNX2), which kick-start osteogenic differentiation via enhancing expression of osteogenic genes and regulating development into osteocytes. [20] [21] [22] [23] [24] Preadipocyte factor 1 (pref-1), a member of the epidermal growth factor-like protein family acts to inhibit adipogenesis in bones. [25] In contrast, peroxisome proliferator activated receptor gamma (PPARc) and Notch 1 are ligands that ensue signalling pathways which promote adipogenesis and inhibit osteogenesis; PPARc can also interact with and inhibit RUNX2-dependent genes, suppressing its osteogenic activity. [26] Whether the matrix surrounding MSCs is osteogenic or adipogenic partially controls the release of RUNX2 and PPARc. [23] Thus, another determining factor is cell shape and the density of local tissue environment; human BMSCs in culture that were plated at lower densities, allowed to spread, adhere, stretch and flatten preferentially became osteoblasts, whereas those that remained round, huddled, and were plated at high densities underwent adipogenesis. [27] Type II collagen also plays a role in osteogenic differentiation, bone development and fracture healing. [28] Culturing MSCs in and inducing their binding to a type II collagen surface which is later calcified has been shown to promote osteogenesis over adipogenesis via greater expression of RUNX2, osteocalcin and alkaline phosphatase (ALP), increased calcium deposition, expanded cell morphology and increased spreading area. [29] Phosphorylation levels of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) also increase in the presence of type II collagen, which activate downstream signalling pathways towards osteogenic differentiation. Highlighting the importance of such mechanisms, partially deleted type II collagen genes in mice have been shown to result in chondrodysplasia dwarfism, delayed mineralisation, limited endochondral bone and epiphyseal growth plate development in some long bones. [30, 31] Bone homeostasis is additionally under control of an array of hormones, one of which includes parathyroid hormone (PTH). PTH controls bone remodelling and blood calcium levels; low calcium levels increase the responsiveness of osteoblasts to any increase in PTH via an increase in PTH receptor expression. [32] In order to maintain calcium levels within a narrow range, PTH modulates calcium resorption from bones into circulation, increasing renal calcium absorption and phosphate excretion, and increasing the production of activated vitamin D, calcitriol, which subsequently increases dietary calcium absorption via the intestines. [33] The role of PEDF in bone homeostasis Pigment epithelium-derived factor is involved in bone development, ossification and remodelling. It is produced by chondrocytes in the resting, proliferative and upper hypertrophic regions of the epiphyseal growth plate, osteoblasts lining bone spicules in ossification zones and those lining cortical periosteum. [34] The epiphyseal growth plate, found in children and adolescents, is formed from hyaline cartilage at the ends of bones and is responsible for the lengthening of long bones via replacement of such cartilage with osteoblasts. The invasion of capillaries in this cartilage is necessary during postnatal growth to allow entry of cells which contribute to such bone formation and this angiogenic process is mediated by PEDF and VEGF. [35] If the SERPINF1 gene is mutated, the patient's level of PEDF are diminished and associated with bone defects and increased fracture risk. [36] The balance between PEDF and VEGF appears to influence both MSC differentiation into osteocytes/adipocytes and angiogenesis within newly formed tissues and is thus important for osteoblastogenesis. [37] VEGF is generated by osteoblast precursors in cartilage of future bone, has been reported to promote osteoblastic maturation and mineralisation of the matrix, and plays a critical role in multiple stages of bone repair. [38] [39] [40] In murine models, the inclusion of VEGF in grafts of demineralised bone matrix significantly increased the rate of bone formation and mineralisation. [41] An age-related reduction in VEGF levels may be related to decreased bone density and vascularity, and development of osteoporosis. [42] MSCs have the ability to differentiate into an osteoblast, adipocyte or chondrocyte, and VEGF, like PEDF, induces their commitment to an osteocyte lineage. [18] An in-vitro study demonstrated that the local levels of PEDF had a regulatory effect on the amount of VEGF produced by MSCs, suggesting that production of PEDF and VEGF is coordinated to maintain a balance between the factors and maintain homeostasis regarding mineralisation and resorption. [37] Following on from this, a disruption in this VEGF/PEDF balance has the potential to contribute to age-related changes in bone density. However, the regulation of the balance of PEDF/VEGF, particularly with respect to increasing age, is not clear and requires further investigation.
Pigment epithelium-derived factor also appears to enhance the expression of genes involved in osteoblastic differentiation and mineral deposition, as evidenced by its presence promoting MSC differentiation and cell maturation, and an increase in alkaline phosphatase (ALP) activity. [43, 44] This is achieved in multiple ways. PEDF signals through mitogen activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK pathway) and ALP pathways, thus activating downstream signalling cascades that lead to osteogenic differentiation. [45] ALP is a key enzyme in the early stages of bone tissue formation, osteoblast commitment and calcification; ALP deficiency delays or prevents mineralisation of the osteoblast matrix. [43] MAPK/ERK mediates transforming growth factor-b (TGFb) and fibroblast growth factor-2 (FGF-2) stimulated osteoblast proliferation. These factors are therefore also important in inducing the MAPK/ERK pathway also regulates deposition of matrix protein, affecting type I collagen, bone sialoprotein and osteopontin, which function as mineralisation scaffolds, hydroxyapatite initiation sites, and mineralisation modulators, respectively. To support these hypothesised pathways, forced suppression of PEDF synthesis has been shown to result in decreased ALP activity, and a reduction/retardation of mineral deposition. [43] Matrix mineralisation involves actions of factors such as osteocalcin, sclerostin (Sost) and dentin matrix protein (DMP-1), which are produced by osteoblasts and osteocytes. [46, 47] Sost is secreted by osteocyte dendrites and is a potent inhibitor of bone formation, exerting function via modifying Wnt signalling pathway thus giving it the ability to increase bone mass. [48] Supplementation by exogenous PEDF has been shown to inhibit Sost expression and thus provides insight into how PEDF regulates mineralisation. [47] PEDF also has a direct effect on osteoid tissue generation via the Wnt pathway. Wnt functions as an activator of intracellular signalling cascades, often via ß-catenin protein transducers, with binding of its ligands such as Wnt3a to multiple receptor sites. The Wnt10b ligand promotes a shift in cell fate to osteoblast lineage via activation of RUNX2 and suppression of PPARc. [49, 50] Furthermore, a study in mice show that overexpression of certain Wnt receptors can lead to reduced osteoblast apoptosis and thus a higher bone mass.
[51] PEDF appears to regulate Wnt signalling via cell surface receptors, rather than intracellularly, one of which is low-density lipoprotein receptor-related protein 6 (LPR6). [52] PEDF binds to LRP6 with high affinity, thereby blocking signalling induced by the Wnt ligand. However, these findings are pertinent to the retina, and has not yet been performed in the context of bone tissue.
Along with enhancing the formation of new bone tissue, PEDF also appears to be involved in preventing bone resorption, a process by which osteoclasts break down existing bone. PEDF is expressed by osteoclasts and appears to inhibit their formation and survival. [53] This is achieved via inhibition of receptor activator of nuclear factor kappa-ß ligand (RANKL), an osteoclast differentiation factor. PEDF also increases osteoprotegerin (OPG) expression which further inhibits RANKL. Overall, inhibition of RANKL expression prevents differentiation into osteoclasts (Figure 2 ).
Potential therapeutic applications of PEDF
Attributable to PEDF having the ability to influence both the rate and location of bone formation, it has the potential to be utilised in therapy for trauma, or various bone disorders, such as OI type VI or osteosarcoma. Attributable to the need of a tumour for extensive vascularisation and blood supply to feed rapidly dividing cells, PEDF's antiangiogenic activity is ideal. In addition, its ability to inhibit the migration of endothelial cells and promote apoptosis may also be useful. [16] Several studies have been conducted showing inverse relationships between PEDF levels and lung cancer, [54] prostate cancer, [55] hepatocellular Figure 2 The effects of pigment epithelium-derived factor in both forming and maintaining bone tissue. [Colour figure can be viewed at wileyonlinelibrary.com] carcinoma, [56] pancreatic adenocarcinoma, [57] osteosarcoma, [16] neuronal cancers including glioma [58] and neuroblastoma, [59] and peripheral nerve sheath tumours. [60] ( Table 1) . Pigment epithelium-derived factor has shown promise in several animal studies pertaining to osteosarcoma management and treatment. PEDF, being expressed at high levels in the resting, proliferative and upper hypertrophic layers of epiphyseal growth plate, is partially responsible for the resistance of these cartilage areas to osteosarcoma invasion due to inhibition of vascularisation. [73] PEDF has been shown to actively regulate osteosarcoma cell cycling via inhibiting the entry of cells into the S-phase of mitosis. [74] PEDF also induced apoptosis, however only orthotopic (cells injected directly into the site of tumour growth) and not ectopic (injected subcutaneously) tumour growth was suppressed, suggesting that PEDF's inhibition of osteosarcoma proliferation may be dependent on its interactions and influence on the local bone microenvironment specifically. [74] The occurrence of pulmonary metastasis was also restricted in the PEDF-treated mice; the results indicated that PEDF played an antimetastatic role via microenvironment regulation or changes in tumour cell phenotype. Interestingly, similar anti-invasive effects of PEDF have been reported in vivo in further osteosarcoma, glioma and melanoma cell models. [75] [76] [77] Such effects are hypothesised to be due to increased adhesion to collagen I and significant down-regulation of matrix metalloproteinase-9 (MMP-9), an enzyme involved in degradation of the extracellular matrix. Overexpression of MMP-9 is associated with the acquisition of metastatic potential. [77] Further direct antiosteosarcoma actions include PEDF leading to insufficient vascularisation and apoptosis in MG63 human osteosarcoma cells as a result of reduced VEGF mRNA levels and increase in caspase-3/7 activation. [78] It was also found that PEDF suppressed incorporation of [3H]thymidine into MG63 cells, thus inhibiting their DNA synthesis, in a dosedependent manner. [78] Along with reduction of VEGF, the antiangiogenic abilities of PEDF in tumours has been attributed to increased levels of endothelial cell apoptosis mediated by the Fas/Fas-L pathway. [79] In a mouse model of osteosarcoma where PEDF treatment was delayed until the tumours became clinically palpable, application of synthetic peptides derived from PEDF was found to be able to reduce tumour size by 47.4% and 53.0%, and pulmonary metastases reduced by 79.8% and 68.1% when treated with 50 and 500 lg/kg of peptides, respectively. [80] Note that the functions of the synthetic peptides were attributed to the active epitopes of PEDF they possessed; thus, whilst the full parent model was not used, the peptides represent the actions of PEDF. However, despite the reduction in tumour volume, the rate of apoptosis and necrosis of the tumour cells were no different in treatment and control groups possibly due to the advanced size of the tumours; they had already advanced beyond their vasculature and thus readily underwent apoptosis and necrosis independent of PEDF. This indicates that apoptosis is not a mechanism of PEDF's reduction in tumour size in more advanced tumours, but rather in the early stages of the tumour lifespan. Currently, the models of inhibition of osteosarcoma growth and metastasis have been limited to in vitro and animal models; no evidence in humans is yet available. Barriers to the utilisation include the determination of safety profiles and development of safe and effective delivery mechanisms for PEDF to the tumour environment. Successful delivery of PEDF has been achieved by a thermal and pH responsive chitosan gelling matrix system composed using dipotassium orthophosphate; given that strength of the hydrogel allowed PEDF to be released at a sufficient rate, the PEDF released was able to significantly reduce osteosarcoma cell proliferation and increased adhesion, however, metastatic potential was not affected. [81] However, when coadministered with a second chitosan hydrogel containing the chemotherapeutic doxorubicin, tumour volumes were reduced by an even further margin and pulmonary metastases decreased by approximately eightfold (Figure 3) .
Similar results have been achieved by chitosan microparticle delivery of a plasmid expressing PEDF to orthotopic osteosarcoma, including the inhibition of metastases. [82] . A mutation in the SERPINF1 gene resulting in reduced endogenous concentrations of PEDF is involved in the pathogenesis of OI type VI, a disorder ensuing a wide variation of phenotypes but regularly characterised by bone fragility, bone pain and increased risk of fractures. [83] Therefore, it would be reasonable to hypothesise that supplementation by exogenous PEDF or an increase in PEDF expression may have a positive effect in the management of OI. Several studies have investigated this idea, resulting in conflicting outcomes. Recently, an in vivo study found that restoration of PEDF levels in a murine model of OI type VI increased cortical and trabecular bone mass and ductility, thus lessening brittleness. [84] The specific outcomes on bone microarchitecture differed with the age of the subject; if young, the effect on trabecular number (a measure of bone texture and quality) was more prominent, whereas mature mice displayed a larger increase in trabecular thickness. On the contrary, it has been separately reported that an induced increase in hepatic PEDF secretion resulting in a blood level well above that of the normal physiological range (>1000 lg/ml) did not improve symptoms, and the low bone mass of the subjects was not corrected. [85] The authors hypothesised that the contradicting results may be due to the variation in serum PEDF levels; where no effect was seen, the levels were significantly higher than the normal physiological range. Indeed, evidence exists that PEDF may exhibit paradoxical effects with extreme Animal -intratumoral injection of a PEDF expressing plasmid, [64] IV injection of MSCs expressing PEDF through lentiviral transduction [61] Significant inhibition of preestablished tumour volume [56] ; suppression of tumour growth and inhibition of metastases development [61] Mechanisms not investigated [56] Inhibition of tumour angiogenesis; mechanisms not further investigated [61] Lung cancer Animal -intraperitoneal injection of recombinant PEDF [62] Inhibition of tumour growth and induction of apoptosis [62] Upregulation of Fas-L/Fas death signalling pathway; activation of caspase-8 & 9; increase of p53 expression [62] Glioma Animal -adeno-associated virus-PEDF and MSCs overexpressing PEDF delivered to glioma xenografts [63] Animal -introduction of purified recombinant-PEDF [64] Animal -introduction of human PEDF expression to glioma xenograph [58] Increased apoptosis and inhibition of angiogenesis; suppression of glioma growth [63] Increased apoptosis, prevention of proliferation and metastasis, inhibition of angiogenesis [58, 64] Molecular mechanisms not investigated [63] Increase of p53 and Bax expression, Bcl-2, MMP-9 and VEGF downregulation, arrest in G 0 /G 1 cell cycle stage [64] Downregulation of MMP-9, VEGF & bFGF, enhancement of p53, csapase-3 & TSP-1 [58] Neuroblastoma Animal -injection with recombinant PEDF and measure of PEDF influence on antitumour Schwann cell population [59] Animal -recombinant adenoassociated virus vectormediated PEDF delivery [65] Angiogenesis inhibition, induction of tumour cell differentiation leading to reduced aggressiveness, supporting expansion/reducing apoptosis of Schwann cell population [59] Neuroblastoma angiogenesis inhibition, restriction of tumour growth [65] Alteration of PEDF/VEGF ratio to favour PEDF, other un-investigated mechanisms [59] Decrease of intratumoural VEGF expression, other un-investigated mechanisms [65] Pancreatic adenocarcinoma
In-vitro -cultures of murine and human neoplastic pancreatic epithelial cells [66] Attenuation of inflammatory reaction, reduction of fibrosis [66] Suppression of macrophage migration, TGF-ß1, NFjB, IL-22 & IL-28 synthesis, reduction of type I collagen deposition [66] Prostate cancer In-vitro -cultured human prostate cancer cells [67] In-vitro -cultured prostate cancer cells and bone-marrow derived macrophages [68] In-vitro -cultured human prostate cancer cells [69] Inhibition of cell proliferation, and cell invasion & chemotaxis [67] Induction of macrophage migration towards cancer cells, increase of phagocytosis and tumouricidal effects [68] Increased cell adhesion, decreased cell invasion [69] Limitation of IL8 production via PPARc and subsequent NFjB inactivation [67] Stimulation of macrophage superoxide production, upregulation of PEDF receptors ATP5B & PNPLA2 on macrophages, blockage of CD47 antiphagocytic signal [68] Decreased FAK phosphorylation, decreased MT1-MMP expression [69] Peripheral nerve sheath tumours
Animal -xenografted tumour model [60] Reducing tumour cell proliferation & viability, inducing apoptosis, inhibition of angiogenesis and decrease in vessel density [60] Inhibition of VEGF expression, activating caspase-3/7 cascade [60] Melanoma Animal -mouse model of uveal melanoma AE PEDF knockout [70] In-vitro -(collagen cell bed) and in-vivo -mouse model injected with melanoma A375 melanoma cells overexpressing PEDF [71] Decrease of progression of hepatic metastases, reduction of tumour blood vessel density and type III collagen [70] Suppressed lung extravasation of aggressive melanoma, promoted elongated, adhesive cell morphology, blocked movement of MT1-MMP to cell surface [71] Mechanisms not investigatedhypothesised VEGF blockage, reduction of activated hepatic stellate cells [70] Decreased RhoA and increased Rac1 activation via upregulation of Rac1-GEF, DOCK3 and down-regulation of Rac1-GAP and ARHGAP22 [71] concentration. [86] It may be that the PEDF must be produced locally rather than distally to induce a paracrine or autocrine effect on bone formation and density.
Pigment epithelium-derived factor also has the potential to be used in bone regeneration therapies, for skeletal disease, trauma, osteosarcoma or congenital malformations. Being able to generate osteoid tissue from MSCs or other cell types including adipose-derived stromal cells, which like MSCs have multidifferentiative potential, could allow PEDF to induce new bone tissue formation. [87] Current evidence is promising, albeit limited. One study demonstrated that PEDF encapsulated within chitosan microparticles could induce spontaneous osteoid tissue generation, and supported the viability of coadministered MSCs postperiosteal injection into a muscle adjacent to the tibia in mice. [82] A brief investigation into potential adverse effects [72] In vitro -cultured human MDA-MB231 cells [69] Inhibition of breast cancer growth and metastasis [72] Inhibition of metastasis [69] Downregulation of fibronectin via laminin receptor, MMP-2 & MMP-9 reduction via p-ERK and p-AKT pathways [72] Decreased expression of MT1-MMP, decreased FAK phosphorylation [69] ARHGAP22, Rho GTPase activating protein 22; ATP5B, adenosine triphosphate synthase subunit beta; Bax, Bcl-2-like protein 4; bFGF, basic fibroblast growth factor; CD47, cluster of differentiation 47; DOCK3, dedicator of cytokinesis 3; Fas-L, Fas ligand; FAK, focal adhesion kinase; IL-2-interleukin-2; IL-8, interleukin-8; MMP-9, matrix metalloproteinase-9; MSC, mesenchymal stem cell; MT1-MMP, membrane type-1 matrix metalloproteinase; NFkß, nuclear factor kappa ß; PEDF, pigment epithelium-derived factor; PNPLA2, Patatin-like phospholipase domain-containing protein 2; PPARc, peroxisome proliferator-activated receptor gamma; Rac-1, Ras-related C3 botulinum toxin substrate 1; Rac-1-GAP, Rac-1 GTPase activated protein; Rac-1-GEF, Rac-1 guanine nucleotide exchange factors; RhoA, Ras homolog family member A; TSP-1, thrombospondin 1; VEGF, vascular endothelial growth factor. Figure 3 A summary of the influence of pigment epithelium-derived factor on osteosarcoma. Pigment epithelium-derived factor is produced endogenously from the epiphyseal growth plate, hepatocytes and adipose tissue, however, some evidence arises from the exogenous administration of pigment epithelium-derived factor to subjects. In summary, overall effects in osteosarcoma lead to inhibition of the cancer growth, and a reduction of metastasis which are typically pulmonary. [Colour figure can be viewed at wileyonlinelibrary.com]
post PEDF-chitosan microparticle treatment found no unwanted reactions pertaining to reduction of glucagon releasing alpha cells, insulin-releasing beta cells or somatostatin-producing delta cells, and the potentially problematic antiangiogenic properties of PEDF did not detract from proper bone formation. A second study confirmed the efficacy of PEDF encapsulated within alginate beads (rather than chitosan) to induce osteogenesis, either with or without MSCs, has also returned positive outcomes. PEDF appeared to induce osteoblastogenesis both with and without coadministered MSCs; the authors suggested that PEDF utilised migrating cells from adjacent adipose tissue and transdifferentiated them to an osteogenic lineage. [88] A further study [89] involving PEDF encapsulated within gelfoam (a surgical sponge with haemostatic properties) which was then implanted into the skeletal muscles of mice, displayed that the serpin was able to induce the transdifferentiation of skeletal myocytes to osteoblasts, and promoted mineralisation of both the muscle and adipose tissues surrounding the implant sites.
Potential adverse effects of PEDF treatment
Knowledge of potential adverse or dangerous effects of PEDF is required for it to be utilised safely in future therapies. Currently, there is evidence that suggests that PEDF is associated with metabolic disorders including polycystic ovarian syndrome, type 2 diabetes mellitus, gestational diabetes and obesity; all with the central pathology of insulin resistance. [13] [14] [15] 90] It has been shown that PEDF is synthesised by preadipocytes at levels much higher than those from other primary cells, suggesting that the immature adipocytes in newly forming adipose tissue may be the source of raised PEDF levels. [91] In addition, it has been found that waist circumference, triglycerides, serum creatinine and TNF-a correlate with PEDF levels in type 2 diabetic patients with visceral obesity. [92] However, whether PEDF is the causative player in such pathologies or if its elevated production is a counter player working against disease is still under investigation, as many studies only find a correlational relationship between PEDF and metabolic disorders. In the body, PEDF acts as a lipolytic adipocytokine, stimulating mobilisation of free fatty acids resulting in ectopic lipid deposition, and potentially inducing insulin resistance. This metabolic activity appears to occur via multiple mechanisms, including PEDF's influence on adipose triglyceride lipase (ATGL), reduction of fatty acid oxidation and suppression of gene expression of ß-oxidation/oxidative metabolism proteins. [93] ATGL activation leads to the release of bioactive lipids and this appears to be required in PEDF's inhibition of insulinmediated glucose uptake. Supporting the hypothesis, ATGL knockout mice display no change in insulin sensitivity upon introduction of exogenous PEDF. [93] In vitro, human adipocytes show decreased insulin-stimulated Akt phosphorylation and significant activation of NF-jb in the presence of PEDF, which reduces insulin sensitivity. [2] In addition, acute PEDF administration is linked to activation of proinflammatory kinases ERK 1/2, IKK and JNK in both the liver and muscle of mice, resulting in reduced insulin signal transduction and sensitivity in peripheral tissues. With respect to inflammation, PEDF is involved in the induction and mediation of the cytokine storm that accompanies inflammatory disorders. When PEDF induces lipolysis, free fatty acids are produced that stimulate Toll-like receptor mediated signalling, which activates IKKb and JNK and thus subsequent cytokines are released, including IL-1, IL-8 and TNFa. This outcome is additionally achieved via phosphorylation of insulin receptor substrate-1, and blockage of advanced glycation end-product-mediated activation of Rac-1. [94] Conversely, a separate report showed that whilst lipolysis was increased in mice when adipose tissue PEDF secretion was increased, no change in energy expenditure and metabolic substrate utilisation, adiposity, inflammation in adipose tissues, glucose and insulin tolerance tests or body mass was observed.
[95] Further investigation highlighted that the higher PEDF levels reported in metabolic dysfunction appeared to arise as a result of the disease inducing liver damage, as opposed to being a cause of the metabolic dysfunction itself.
[96] However, it is important to note that neither of these studies involved the introduction of high levels of exogenous PEDF, only endogenous production. Thus, the multiple studies that show PEDF playing a direct role in the development of insulin resistance, inflammation and additional metabolic dysfunction cannot be disregarded. PEDF has also been described as a mediator of mitochondrial dysfunction, which is a known influence on insulin resistance because glucose and lipid metabolism is largely dependent on mitochondrial ATP production.
[97] The serpin reduces free fatty acid oxidation in myocytes and skeletal muscle, generating a lipotoxic environment. Evidence suggests that higher levels of free fatty acids are associated with mitochondrial dysfunction in 3T3-L1 adipocytes.
[98] However, the PEDFinduced mitochondrial dysfunction hypothesis requires further evidence to be confidently proven.
Conclusion
Human bone homeostasis is under the control of a plethora of mediators and mechanisms. Relevant actions of PEDF include the regulation of vasculature within forming bone tissues, promoting osteoblastogenesis from MSCs, enhancing mineral deposition and preventing resorption. PEDF has shown promise in several experimental models of de novo bone generation, and possesses multiple anticancer and more specifically antiosteosarcoma actions. However, higher PEDF levels are associated with several metabolic dysfunctions resulting in insulin resistance and metabolic inflammatory disorders. Further in vivo studies involving the application of external, therapeutic doses of PEDF are needed for clarification and a confident picture of PEDF's possible efficacy vs adverse effect profile. In conclusion, the existing evidence gives PEDF the potential to be utilised as an agent in future therapies for the management of bone disorders including osteosarcoma or bone regenerative therapy, with possibly improved therapeutic outcomes compared with current treatment options.
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